DMIIU SCHEDULE 13G: SEC filing
Karpus Management, Inc.
Filed with the SEC on · accession 0001072613-26-000875
DMIIU filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 13, 2026. Karpus Management, Inc. filed a Schedule 13G reporting beneficial ownership of 3,300,023 shares (5.18%) of Drugs Made In America Acquisition II Corp. as of September 30, 2026.
Summary of the filing
Karpus Management, Inc. filed a Schedule 13G reporting beneficial ownership of 3,300,023 shares (5.18%) of Drugs Made In America Acquisition II Corp. as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b) by a registered investment adviser.
Key details
✦ Ask GOAX AI about this filing — what it means for DMIIU, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for DMIIU?
Click hereFrequently asked questions
What did DMIIU file with the SEC on Nov 13, 2026?
DMIIU filed a SCHEDULE 13G (SEC filing). Karpus Management, Inc. filed a Schedule 13G reporting beneficial ownership of 3,300,023 shares (5.18%) of Drugs Made In America Acquisition II Corp. as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b) by a registered investment adviser.
How do I read a SCHEDULE 13G?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).
Get alerts when DMIIU files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days